Vanda Pharmaceuticals (VNDA) Gains FDA Approval to Proceed with IND for VSJ-110 for Allergic Conjunctivitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. HON
4. KBH
5. MRK
6. HTZ
7. INFY
8. HONA
9. TTWO
10. QCOM

Go back to Vanda Pharmaceuticals (VNDA) Gains FDA Approval to Proceed with IND for VSJ-110 for Allergic Conjunctivitis

Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 2c, Revenues Miss; Offers FY20 Revenue Outlook

October 28, 2020 4:04 PM EDT

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.11, $0.02 better than the analyst estimate of $0.09. Revenue for the quarter came in at $60.31 million versus the consensus estimate of $63.95 million.

Key Financial and Corporate Highlights

Third Quarter of 2020

Total net product sales from HETLIOZ® and... More